These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18276711)

  • 1. Should doctors advocate snus and other nicotine replacements? No.
    Macara AW
    BMJ; 2008 Feb; 336(7640):359. PubMed ID: 18276711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should doctors advocate snus and other nicotine replacements? Yes.
    Britton J
    BMJ; 2008 Feb; 336(7640):358. PubMed ID: 18276710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smokeless tobacco as a nicotine delivery device: harm or harm reduction?
    Benowitz NL
    Clin Pharmacol Ther; 2011 Oct; 90(4):491-3. PubMed ID: 21934719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tobacco smoking, harm reduction, and nicotine product regulation.
    Britton J; Edwards R
    Lancet; 2008 Feb; 371(9610):441-5. PubMed ID: 17920116
    [No Abstract]   [Full Text] [Related]  

  • 5. Snus use in the U.S.: reducing harm or creating it?
    Twombly R
    J Natl Cancer Inst; 2010 Oct; 102(19):1454-6. PubMed ID: 20870974
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized Trial to Compare Smoking Cessation Rates of Snus, With and Without Smokeless Tobacco Health-Related Information, and a Nicotine Lozenge.
    Nelson PR; Chen P; Battista DR; Pillitteri JL; Shiffman S
    Nicotine Tob Res; 2019 Jan; 21(1):88-94. PubMed ID: 29373698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perceived Health Risks of Snus and Medicinal Nicotine Products.
    Hatsukami DK; Vogel RI; Severson HH; Jensen JA; O'Connor RJ
    Nicotine Tob Res; 2016 May; 18(5):794-800. PubMed ID: 26386473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised clinical trial of snus versus medicinal nicotine among smokers interested in product switching.
    Hatsukami DK; Severson H; Anderson A; Vogel RI; Jensen J; Broadbent B; Murphy SE; Carmella S; Hecht SS
    Tob Control; 2016 May; 25(3):267-74. PubMed ID: 25991608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smokeless tobacco use: harm reduction or induction approach?
    Hatsukami DK; Lemmonds C; Tomar SL
    Prev Med; 2004 Mar; 38(3):309-17. PubMed ID: 14766113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Snus and the risk of cancer of the mouth, lung, and pancreas.
    Rodu B
    Lancet; 2007 Oct; 370(9594):1207-8; author reply 1208. PubMed ID: 17920914
    [No Abstract]   [Full Text] [Related]  

  • 11. Does dual use jeopardize the potential role of smokeless tobacco in harm reduction?
    Frost-Pineda K; Appleton S; Fisher M; Fox K; Gaworski CL
    Nicotine Tob Res; 2010 Nov; 12(11):1055-67. PubMed ID: 20847148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harm reduction policies for tobacco users.
    Gartner C; Hall W
    Int J Drug Policy; 2010 Mar; 21(2):129-30. PubMed ID: 19944582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Snus--what should the public-health response be?
    Foulds J; Kozlowski L
    Lancet; 2007 Jun; 369(9578):1976-1978. PubMed ID: 17498796
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association.
    Piano MR; Benowitz NL; Fitzgerald GA; Corbridge S; Heath J; Hahn E; Pechacek TF; Howard G;
    Circulation; 2010 Oct; 122(15):1520-44. PubMed ID: 20837898
    [No Abstract]   [Full Text] [Related]  

  • 15. Tobacco harm reduction: thinking the unthinkable.
    Lawson E
    Br J Gen Pract; 2012 Jun; 62(599):314. PubMed ID: 22687217
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of smokeless tobacco (snus) on smoking and public health in Sweden.
    Foulds J; Ramstrom L; Burke M; Fagerström K
    Tob Control; 2003 Dec; 12(4):349-59. PubMed ID: 14660766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tobacco, nicotine and harm reduction.
    Le Houezec J; McNeill A; Britton J
    Drug Alcohol Rev; 2011 Mar; 30(2):119-23. PubMed ID: 21375611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Harm reduction strategy in tobacco control].
    Gorini G
    Epidemiol Prev; 2011; 35(3-4 Suppl 1):19-32. PubMed ID: 21926451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Misleading conclusions from Altria researchers about population health effects of dual use.
    Glantz SA; Ling PM
    Nicotine Tob Res; 2011 Apr; 13(4):296; author reply 297. PubMed ID: 21350043
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of smokeless tobacco product marketing and use on population harm from tobacco use policy perspective for tobacco-risk reduction.
    Kozlowski LT
    Am J Prev Med; 2007 Dec; 33(6 Suppl):S379-86. PubMed ID: 18021913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.